13 Facts About Tenofovir disoproxil

Tenofovir disoproxil was patented in 1996 and approved for use in the United States in 2001.

Tenofovir disoproxil is used for HIV-1 infection and chronic hepatitis B treatment.

Tenofovir disoproxil is generally well tolerated with low discontinuation rates among the HIV and chronic hepatitis B population.

In vivo tenofovir disoproxil fumarate is converted to tenofovir, an acyclic analog of deoxyadenosine 5'-monophosphate .

Tenofovir disoproxil lacks a hydroxyl group in the position corresponding to the 3' carbon of the dAMP, preventing the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation.

Related searches

Tenofovir disoproxil is a prodrug that is quickly absorbed from the gut and cleaved to release tenofovir.

Tenofovir disoproxil is mainly excreted via the kidneys, both by glomerular filtration and by tubular secretion using the transport proteins OAT1, OAT3 and ABCC4.

Tenofovir disoproxil is a derivative of adenine and this was the chemical starting point for its first published synthesis which was included in patents to the compound.

Tenofovir disoproxil is formed when the diethyl phosphonate group is converted to its acid using trimethylsilyl chloride in the presence of sodium bromide, a further refinement of the original manufacturing route.

Tenofovir disoproxil was initially synthesized by Antonin Holy at the Institute of Organic Chemistry and Biochemistry of the Czechoslovak Academy of Sciences in Prague.

Tenofovir disoproxil can be taken by mouth and is sold under the brand name Viread, among others.

Tenofovir disoproxil is a pro-drug form of tenofovir phosphonate, which is liberated intracellularly and converted to tenofovir disphophate.

Tenofovir disoproxil is available in pills which combine a number of antiviral drugs into a single dose.